Andarix Pharmaceuticals

What Andarix Pharmaceuticals does

Andarix Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Somerville, Massachusetts, developing targeted radiotherapeutics for oncology. The company is built around its proprietary P2045 somatostatin peptide conjugate platform, which forms chelate complexes with radioisotopes and is specifically optimized to bind both the diagnostic imaging agent Technetium-99 (Tc99-P2045) and the therapeutic radionuclide Rhenium-188 (Re188-P2045, branded as Tozaride). The platform exploits the over-expression of somatostatin receptors (SSTR2) on solid tumors, with lead indications in small cell lung cancer, pancreatic cancer, and neuroendocrine tumors — disease areas characterized by limited treatment options and high unmet medical need. Tozaride has received FDA Orphan Drug Designation for both small cell lung cancer and pancreatic cancer, providing 7-year U.S. marketing exclusivity upon approval.

Name

Andarix Pharmaceuticals

Legal name

Andarix Pharmaceuticals Inc

Website

https://andarix.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Andarix Pharmaceuticals is a clinical-stage biopharmaceutical company developing Tozaride (Re188-P2045), a targeted radiotherapeutic using a proprietary somatostatin peptide platform to treat somatostatin receptor-positive cancers including small cell lung, pancreatic, and neuroendocrine tumors.

Ownership category

akta.pro rank

Product category

Targeted Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

Keywords

• Targeted radiopharmaceuticals
• Peptide drug conjugate
• Cancer therapeutics
• Companion diagnostics
• Radiotheranostic platform

Headquarters

HQ city

Somerville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Tozaride (Rhenium 188 P2045) Commercialization: Pre-commercial clinical-stage company developing targeted radiotherapeutics. Revenue will be generated through product sales upon regulatory approval. Strategic partnership with Wuxi Fortune Pharmaceuticals for China market development.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Andarix Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapeutics for oncology based on its proprietary somatostatin peptide conjugate platform (P2045). The company combines the P2045 peptide with therapeutic (Rhenium-188) and diagnostic (Technetium-99) radioisotopes to deliver a theranostic approach that identifies and treats cancer cells overexpressing somatostatin receptors (SSTR2), primarily in lung, pancreatic, and neuroendocrine cancers.

Product overview

Andarix Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapeutics for oncology based on its proprietary peptide targeted radionuclide technology. The company's platform combines a proprietary somatostatin peptide conjugate (P2045) with radioisotopes for both diagnostic imaging and therapeutic applications. The product portfolio includes: (1) Tozaride (Re188-P2045), the lead therapeutic product combining the P2045 peptide with Rhenium-188 for targeted radiotherapy; (2) Tc99-P2045, a companion diagnostic imaging agent using Technetium-99 to identify patients with high SSTR2 expression who are most likely to respond to therapy; and (3) the underlying P2045 peptide platform technology. This theranostic approach enables patient selection through imaging followed by targeted treatment of the same cancer.

Differentiator

Problem solved

Functional benefit

Brands

• Tozaride: Lead product candidate - Rhenium 188 P2045 targeted radiotherapy for small cell lung cancer, pancreatic cancer, and other cancers. Trademark granted by USPTO in 2019.

Products and services

• Tozaride (Rhenium 188 P2045 / Re188-P2045) Tozaride is a targeted radiotherapeutic that combines a high-affinity somatostatin receptor-binding peptide (P2045) with the beta-emitting radionuclide Rhenium-188. It delivers cytotoxic radiation to cancer cells overexpressing somatostatin receptors, particularly in lung, pancreatic, and neuroendocrine cancers, while sparing normal tissues.
• Tc99-P2045 (Technetium-P2045) Companion Diagnostic Tc99-P2045 is a diagnostic imaging agent based on Technetium-99 conjugated to the P2045 peptide. It is used to image patients in real time to identify those with high density of SSTR2 receptors who are most likely to respond to Tozaride therapy, enabling patient selection for personalized treatment.

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Wuxi Fortune PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 September 2017Agreement to develop and commercialize Tozaride for lung and other cancers in China market. Wuxi Fortune acquired certain rights to the China market for Tozaride, a targeted peptide therapy. The companies will collaborate on clinical development. TriPoint Global Equities served as placement agent and financial advisor.
• Tulane UniversitycoreStrategic or Co-development Partner · 1 October 2015Research and development license for Notch Influencing Molecules technology developed by Drs. Li-Chun Sun and David Coy. License includes option to commercialize the technology. Research demonstrates Notch1 activation up-regulates SSTR2 expression, expanding therapeutic applicability of SSTR2-targeted therapy.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Novartis: Global pharma with approved targeted radiopharmaceuticals Lutathera (SSTR-targeted, NETs) and Pluvicto (PSMA-targeted, prostate cancer); the most relevant incumbent competitor for Andarix's SSTR2-targeted Tozaride, with established isotope supply and global commercial reach.
• Advanced Accelerator Applications (Novartis): Novartis-owned radioligand therapy subsidiary that developed and commercializes Lutathera, the first approved SSTR-targeted radiopharmaceutical for NETs; a direct and most established competitor in Andarix's target indication and mechanism.
• Bayer: Global pharma with Xofigo (Ra-223) for bone metastases and a growing radiopharmaceutical platform including the Algeta-acquired assets; relevant incumbent competing in the broader targeted radiopharmaceutical oncology space.

Direct peers

• POINT Biopharma: Clinical-stage radiopharmaceutical company developing PNT2002 (Lu-177 SSTR analog) and PNT2003 (PSMA) for NETs and prostate cancer; acquired by Eli Lilly in 2023, illustrating M&A appetite for late-stage radiopharma assets similar to Andarix.
• RayzeBio: Clinical-stage radiopharmaceutical company developing actinium-225-based targeted radiotherapies for solid tumors; acquired by Bristol-Myers Squibb in 2024 for ~$4.1B, a comparable clinical-stage targeted radiopharma platform.
• Lantheus Holdings: Radiopharmaceutical-focused company with approved imaging agents (e.g., Definity, AZEDRA for rare NETs) and a growing therapeutic radiopharmaceutical pipeline; comparable business model centered on diagnostic and therapeutic radiopharmaceuticals.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing theranostic pairs (e.g., Illuccix for prostate cancer imaging); directly comparable as a small-cap, growth-stage radiopharma company pursuing paired Dx/Tx products in oncology.
• ITM Isotope Technologies Munich: Vertically integrated radiopharmaceutical company combining medical radioisotope production with proprietary targeted radiotherapeutic development for NETs and other solid tumors; comparable as a clinical-stage developer of Lu-177/Y-90-based SSTR-targeted therapies.
• Fusion Pharmaceuticals: Clinical-stage developer of targeted alpha therapies using antibody and small-molecule conjugates with actinium-225; acquired by AstraZeneca in 2024, representing a direct comparable in the targeted radioconjugate space.

Emerging players

• Crinetics Pharmaceuticals: Clinical-stage company developing somatostatin receptor-targeted oral small molecules (e.g., paltusotine) for NETs and acromegaly; competes with Andarix in the SSTR2 therapeutic space via a non-radiopharmaceutical modality.

Market position

Competitive moat3 records

Key risks1 record

Key highlights6 records

Customer concentration

• Xx.com/AndarixPharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Andarix Pharmaceuticals